

Letter to the Editor: Hepatoma in the Elderly—Follow-Up on a Case Report

Last year we reported a patient with hepatoma (IB) who was 95 years old at the time of diagnosis. He was treated with cisplatin intra-arterially. We now have a 5-year follow-up and 4 years of off all therapy. He continues to do well with a normal alphafetoprotein and ultrasound of the liver that shows mainly scar tissue.

Last August he celebrated his 100th birthday. I think your readers will be interested in hearing about this long-term follow-up and continued remission. I use this case as

an example of how age should not be used arbitrarily to exclude patients from therapy.

Paul P. Carbone, MD
Department of Medicine
UW Comprehensive Cancer Center
University of Wisconsin Medical School
Madison, WI 53792-0001